Medications
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma
The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is the third FDA-approved ...
Jun 24, 2024
0
0
